Medical

auranofin

Also found in: Wikipedia.

auranofin

 [aw-ran´o-fin]
a gold-containing compound that is a disease-modifying antirheumatic drug used to treat active rheumatoid arthritis, usually that not adequately controlled by nonsteroidal antiinflammatory drugs, or nondrug therapy such as physical therapy; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

auranofin

(ô-răn′ə-fĭn)
n.
A gold-containing compound used to treat rheumatoid arthritis.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

auranofin

A gold preparation that can be taken by mouth for the treatment of RHEUMATOID ARTHRITIS. A brand name is Ridaura.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
Mentioned in
References in periodicals archive
Concomitant RA medications were permitted at the discretion of the investigator and included: methotrexate, leflunomide, sulfasalazine, antimalarials, auranofin injectable gold preparations, nonsteroidal anti-inflammatory drugs, and/or glucocorticoids at approved doses.[28]
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.
Klegeris, "A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases," Neural Regeneration Research, vol.
crassiceps TGR was obtained by incubating an enzyme aliquot in the presence of a 4:1 molar excess of the irreversible inhibitor auranofin [14].
A number of new molecules have been identified as inhibitors of IL-1[beta] processing (glyburide, parthenolide, CRID3, auranofin, isoliquiritigenin, [beta]-hydroxybutyrate, and MCC950); however, confirming their clinical utility will require additional time and research [24].
cDMARDs n (%) Patients with at 11,511 (91.9%) least one treatment Methotrexate 9,508 (75.9%) Hydroxychloro quine 3,527 (28.2%) Leflunomide 3,275 (26.1%) Sulfasalazine 2,340 (18.7%) Sodium aurothiomalate 114 (0.9%) Azathioprine 98 (0.8%) Cyclosporine 89 (0.7%) Auranofin 43 (0.3%) Penicillamine 28 (0.2%) Cyclophosphamide 10 (0.1%) bDMARDs n (%) Patients with at 3,697 (29.5%) least one treatment Etanercept 1,545 (12.3%) Adalimumab 1,329 (10.6%) Tocilizumab 618 (4.9%) Abatacept 481 (3.8%) Golimumab 376 (3.0%) Rituximab 339 (2.7%) Certolizumab pegol 273 (2.2%) Infliximab 68 (0.5%) Anakinra 3 (<1.0%) Table 3: Change in DAS28-ESR scores over a 6-month period.
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.